Definitive Contract 75D30118C02984
Award Date 9/1/18
Potential Completion Date 8/31/23
Potential Value $35M
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Durham, NC 27703, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Biocryst Pharmaceuticals Inc., a biotechnology company specializing in small molecule drugs for rare diseases. The $47,755,722.77 cost-plus-fixed-fee contract is for the development of medical countermeasures for biodefense and emerging infectious diseases. The contract has a base period from September 16, 2013, to September 15, 2017, with two option periods...
- Biocryst Pharmaceuticals Inc. has been awarded a delivery order valued at $357,245.48 for a bulk purchase of ORLADEYO (berotralstat), a specialized pharmaceutical treatment for hereditary angioedema. This award, issued on March 12, 2024, with an ultimate completion date of March 11, 2025, represents a 2025 price increase for 3 of 13 quantity line items. The contract utilizes firm fixed pricing under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and carries no set-aside...
- This federal contract award is for the delivery of BEROTRALSTAT HCL 150MG CAP (trade name ORLADEYO 150MG CAP) to the U.S. Department of Veterans Affairs (VA). The $379,348.93 contract was awarded to Biocryst Pharmaceuticals Inc., a biotechnology company that specializes in developing small molecule drugs for rare diseases. This is a Firm Fixed Price delivery order placed under Biocryst's Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs (FSS-61-IB). The contract has an...
- This federal contract award is for ORLADEYO EMERGENT, a pharmaceutical product, to Biocryst Pharmaceuticals Inc. as the prime contractor. The contract has a ceiling value of $29,649.88 and is a delivery order under Biocryst's Federal Supply Schedule (FSS) contract (36F79721D0166) for Pharmaceuticals and Drugs with the Department of Veterans Affairs (VA). Biocryst is a biotechnology company that specializes in the development of small molecule drugs for rare diseases, and it primarily supplies...
- This federal contract award to Biocryst Pharmaceuticals Inc. is for the delivery of the pharmaceutical product ORLADEYO (berotralstat) to the Veterans Integrated Service Network 20 (VISN 20), a civilian healthcare agency under the Department of Veterans Affairs (VA). The fixed-price delivery order has a ceiling value of $360,000.00 and a period of performance through September 30, 2026. The contract is not set aside and is awarded under Biocryst's existing Federal Supply Schedule (FSS) contract,...
- This is a $65,867,803.99 definitive contract awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) to VIR Biotechnology, Inc., a self-certified small disadvantaged business. The contract is for the development of pre-exposure prophylactic monoclonal antibodies for the prevention of influenza illness and medical countermeasures for other emerging pathogens with pandemic potential. This contract was awarded under a Broad...
- This federal contract award, with a ceiling value of $360,378,153.90, was issued by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Regeneron Pharmaceuticals Inc. for the development of "Novel Antibodies Against Influenza Virus, Emerging, Re-Emerging, and Pre-Emerging Pathogens." The contract is a Definitive Contract with a Cost Sharing pricing type and has an ultimate completion date of September 24, 2027. The award is not associated with a set-aside...
- This federal contract award to Protein Sciences Corp, a for-profit manufacturer, was made by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS). The $14,675 firm-fixed-price purchase order is for the provision of tested influenza virus proteins. The contract does not have a set-aside designation. Protein Sciences has received multiple previous federal contract awards from the HHS Office of the Assistant Secretary...
- This federal contract award is for the development of CD388 as a long-lasting prophylactic anti-viral option to protect against the health impacts caused by influenza. The $339,189,481.00 definitive, cost-plus-fixed-fee contract was awarded to Cidara Therapeutics Inc., a for-profit organization, by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, on September 30, 2025. The contract has an ultimate completion date of July 3, 2030 and was not set aside for...
- <p>The U.S. Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response, awarded a Firm Fixed Price Delivery Order contract to MedImmune LLC for "DRUGS AND BIOLOGICALS" with a ceiling value of $2,100,000.00. This contract was issued under the Pandemic Influenza Preparedness and Response 2012-2016 Master IDIQ contract vehicle. The contract does not have a set-aside designation and is scheduled for completion by December 31, 2013.</p>